CytoDyn Inc. CYDY Archives - Page 4 of 5

TuesdaySep 11, 2018 9:22 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) to Host Conference Call on September 13

Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that the company’s management will host an investment community conference call to provide a business update on Thursday, September 13, 2018 at 4:00 p.m. ET. To join the conference call from the U.S. or Canada, dial 877-407-2986. To join the international line, dial 201-378-4916. The company will provide a live audio webcast that will be available for 60 days on its corporate website. CYDY encourages all web participants to go to the website 15 minutes before the call to register, download and install any required software. In addition, a replay of the…

WednesdaySep 05, 2018 9:05 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) to Develop PRO 140 as Therapy for Triple-Negative Breast Cancer

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning detailed its plan to develop PRO 140 (leronlimab) as a therapy for metastatic triple-negative breast cancer. Per the update, previously announced findings from preclinical studies showed the ability of PRO 140 to block human breast cancer cellular invasion in a surrogate assay for metastatic breast cancer. “We plan to aggressively pursue the development of PRO 140 as a therapy for women with metastatic triple-negative breast cancer, which is in keeping with our strategy to evaluate PRO 140 in certain cancers and immunological indications where CCR5 antagonism has shown initial promise,” Nader Pourhassan,…

TuesdaySep 04, 2018 3:20 pm

QualityStocksNewsBreaks – Why CytoDyn Inc. (CYDY) is “One to Watch”

Biotechnology company CytoDyn (OTCQB: CYDY) is focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. A recent article discussing the company reads: “The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are…

TuesdayAug 28, 2018 9:40 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Enters Definitive Agreement to Acquire ProstaGene, Announces Key Addition to Leadership Team

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its entry into a definitive agreement to acquire privately held ProstaGene, LLC. The company also confirmed that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and CEO of ProstaGene, will join CytoDyn as interim chief medical officer. Following close of the acquisition, which is expected in November, Pestell will transition to the role of chief medical officer. “We are honored to soon have world-renowned cancer researcher Dr. Richard Pestell join CytoDyn as our Chief Medical Officer, with responsibility for leading all PRO 140 programs in non-HIV indications,” Nader Pourhassan, Ph.D.,…

MondayAug 27, 2018 10:05 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) President and CEO Discusses Company Research in Interview on Uptick Newswire’s “Stock Day” Podcast

Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that the company’s president and CEO Nader Pourhassan was interviewed on Uptick Newswire’s “Stock Day” Podcast. Among other highlights, Pourhassan discussed the company’s main product, a humanized monoclonal antibody, which has demonstrated positive results in HIV patients in a human clinical trial. The antibody has received fast-track designation with the FDA, with the potential of approval in early 2019. In addition, Pourhassan discussed a letter of intent and acquisition of a company with advanced cancer treatment and the company’s newly-hired board member, Michael Klump. To listen to the full interview, visit http://ibn.fm/4qSie…

FridayAug 24, 2018 10:30 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Developing Therapeutic Anti-Viral Agent as Potential Alternative to Current HIV Treatment Options

Biotechnology company CytoDyn (OTCQB: CYDY) remains focused on the development of its new anti-HIV treatment, PRO 140. An article discussing the company’s therapeutic anti-viral agent reads: “The development of PRO 140 is of particular interest, because it could allow people living with HIV to take just one weekly dose instead of the daily pills required by current therapies. … An antibody rather than a drug, PRO 140 works by blocking the most prevalent HIV subtype from entering healthy cells, thus protecting them from infection. Recognizing the treatment’s potential, the FDA has designated PRO 140 a fast-track candidate. To qualify for…

TuesdayAug 21, 2018 1:35 pm

CytoDyn Inc. (CYDY) Plans to File IND for Clinical Trial of PRO 140 in Colon Carcinoma Patients following Significant Preclinical Results

PRO 140 has been shown effective in inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model PRO 140 extended the lives of treated mice and reduced tumor growth by more than 50 percent CytoDyn was recently featured favorably in a report by a leading independent small cap media portal Biotechnology company CytoDyn Inc. (OTCQB: CYDY) recently announced exciting progress (http://ibn.fm/thpLl) in the development of PRO 140 (leronlimab), its novel humanized CCR5 monoclonal antibody, which has multiple therapeutic indications including treating HIV, cancer and inflammatory conditions. In preclinical studies conducted over the past year,…

FridayAug 17, 2018 11:33 am

CytoDyn Inc. (CYDY) is “One to Watch”

PRO 140 is a leading monoclonal antibody/viral-entry inhibitor therapy under development for two different Human Immunodeficiency Virus (HIV) indications and is also being pursued for multiple opportunities in other immunologic indications such as autoimmune disease, chronic inflammation, certain cancers, and transplant rejection During 2017, 1.8 million people became newly infected with HIV, bringing the global total to 36.9 million people living with HIV (World Health Organization) Market potential for PRO 140 used as an anti-viral agent in combination with HAART is $1.2 billion; as a monotherapy maintenance/single-drug therapy the market is estimated at $3.8 billion CytoDyn Inc. (OTCQB: CYDY) is…

ThursdayAug 16, 2018 12:08 pm

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Advances Development of HIV Single Agent Therapy

Biotechnology company CytoDyn (OTCQB: CYDY) recently reported significant developmental progress during phase 3 trials for its PRO 140 monotherapy for human immunodeficiency virus (HIV) after observing enhanced response rates at higher doses of the treatment (http://ibn.fm/yuYub). An article discussing the company’s progress reads: “The dosage increase will apply to all newly enrolled patients but also to current trial participants who failed to maintain suppressed HIV viral load on a lower dose. Approximately 70 percent of trial participants who started PRO 140 at 525 mg and have been undergoing treatment between one and nine months are achieving HIV viral load suppression,…

WednesdayAug 15, 2018 12:41 pm

CytoDyn Inc. (CYDY) Sees Promising HIV Treatment Trial Results, Gets Go-Ahead to Raise Dosage

Response rate to PRO 140 rose from 40 percent at 350mg dose to 70 percent at 525mg Institutional Review Board (IRB) allows trials of viral-entry inhibitor to continue at 700mg dose PRO 140 is an FDA fast-track candidate Following clinical trial results showing that its new anti-HIV treatment is more effective at higher dosages, biotechnology company CytoDyn Inc. (OTCQB: CYDY) is set to give trial participants an increased weekly dose of PRO 140 (http://ibn.fm/oyLRe). The latest round of trial results showed that the response rate among trial participants treated with the viral-entry inhibitor rose from 40 percent at a 350mg weekly…

Site Search

Company Search

Tag: CytoDyn Inc. CYDY